Calcitonin for Treating X-linked Hypophosphatemia


Hypophosphatemic Rickets, X Linked Dominant

What is the purpose of this trial?

X-linked hypophosphatemia (XLH) is the most common form of inherited rickets in the United States. It also causes bone disease in adults. XLH is caused by overproduction of a hormone call FGF23, which makes the body waste phosphate. This study is designed to determine if nasal calcitonin, an already approved drug in the US, can lower blood levels of FGF23 and reduce phosphate wasting in patients with XLH. In this study the investigators will:

  1. Determine whether nasal calcitonin significantly lowers integrated 24-hour blood levels of FGF23 in patients with XLH.
  2. Evaluate whether nasal calcitonin improves serum phosphate levels in XLH.
  3. Assess whether nasal calcitonin improves blood levels of the active form of vitamin D and calcium absorption from the intestine.
  4. Make sure that nasal calcitonin is safe and well tolerated.

Participation Guidelines

18 Years - 80 Years

Click here for detailed information about who can participate in this trial.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Yale University
March 2011
Last Updated:
June 12, 2014
Study HIC#: ID: NCT01652573